decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2002 / AB-02-165
Subscribe or sign in to view the full article.
Article Overview
This article is a Centers for Medicare & Medicaid Services program memorandum that outlines Medicare payment and billing guidance for intravenous levocarnitine in the ESRD population. It is relevant to dialysis facilities, billing staff, and reimbursement professionals who need to understand the covered-use framework, claim form reporting, and effective/implementation timing for this 2003 policy update.
Why This Topic Matters
It clarifies a specific Medicare coverage policy affecting dialysis-related drug billing and helps providers and billers understand the documentation and claims-processing context for the service.
Article Sections
-
Program Memorandum
Introductory memorandum information from DHHS and CMS, including the transmittal and date details.
-
General Information
Background on the policy topic, the population addressed, and the general coverage context for the drug in ESRD care.
-
Billing Requirements
Administrative billing and claims-submission information for intermediaries and carriers, including form and processing references.
-
Medicare Summary Notices (MSN) and Remittance Advice
Reference information related to Medicare denial messaging and related notice language.
What You Will Learn
- The policy area and patient population addressed by the memorandum.
- How the article frames billing and claims-processing guidance for Medicare.
- What implementation and effective-date information is included in the memorandum.
- Which administrative references and notice categories are associated with the guidance.
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Dialysis facility administrators
- Medicare claims processors
- Compliance personnel
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com